



Resource impact statement

Resource impact

Published: 17 February 2021

www.nice.org.uk

Cancer Drugs Fund technology

NICE has recommended niraparib for use within the Cancer Drugs Fund as an option for maintenance treatment for advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

Niraparib will be available to the NHS in line with the [managed access agreement](#) with NHS England. As part of this, NHS England and GlaxoSmithKline have a commercial access agreement that makes niraparib available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.

The resource impact of niraparib will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires or when the results of the managed access agreement data collection are available (anticipated March 2025), whichever is sooner. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in [NHS England's Appraisal and Funding of Cancer Drugs from July 2016 \(including the new Cancer Drugs Fund\) - A new deal for patients, taxpayers and industry](#).

It is estimated that around 2,100 people per year with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer are eligible for treatment with niraparib after a response to first-line platinum-based chemotherapy.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.